by Dr. Ed Weber | Feb 26, 2020 | PCa Commentary
Three new modalities for treatment of advanced prostate cancer are in development that will significantly impact management and extend overall survival: immunotherapy with checkpoint blockade; poly ADP-ribosepolymerase (PARP) inhibitors; and anti-PSMA radioligand... by Dr. Ed Weber | Feb 4, 2020 | PCa Commentary
The ORIOLE TRIAL, “Primary Outcomes of a Phase II Randomized Trial of Observation Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancer,” Phillips et al., Int. J. Radiation Oncology Biology Physics, November 1, 2019 The study had two... by Dr. Ed Weber | Jan 21, 2020 | PCa Commentary
Something big is emerging in the management of men with metastatic (often heavily pre-treated) castration-resistant prostate cancer. A potentially new entry into the regimens of standard-of-care i.e., treatment of men with BRCA 1/2 and ATM mutations with PARP... by Dr. Ed Weber | Dec 4, 2019 | PCa Commentary
Adjuvant radiation and ADT following prostatectomy for high-risk prostate cancer:RTOG Trial 9601, Shipley et al., JCO, 2017 Jan. The findings from this randomized Phase III trial supported the current standard of care for this situation. It compared two treatments... by Dr. Ed Weber | Oct 2, 2019 | PCa Commentary
The suggestion that a few (usually 3 – 5, i.e., ‘oligometastatic’) lesions at the time of biochemical failure after primary treatment might represent an indolent disease state with limited potential for additional spread. This hypothesis was first made in 1995... by Dr. Ed Weber | Oct 2, 2019 | PCa Commentary
* The first study of active surveillance (AS) was started in 1996 at the University of Toronto byDr. Lawrence Klotz. It was first reported in the literature in 2002. In the ensuing 20 years AS has become increasingly accepted as a management approach to biopsy...